tiprankstipranks
Advertisement
Advertisement

IRD Stock Latest News

Opus Genetics: Buy Rating Reiterated on Upcoming Clinical Catalysts and Solid Cash Runway; $10 Price Target Maintained
RatingsOpus Genetics: Buy Rating Reiterated on Upcoming Clinical Catalysts and Solid Cash Runway; $10 Price Target Maintained
1d ago
IRD
Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed
PremiumThe Fly
Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed
10d ago
IRD
LGVN
Analyst Maintains Buy on Opus Genetics, Reiterates $8 Price Target on Multi-Asset Retinal Disease Pipeline and Upcoming BIRD1 Data
PremiumRatings
Analyst Maintains Buy on Opus Genetics, Reiterates $8 Price Target on Multi-Asset Retinal Disease Pipeline and Upcoming BIRD1 Data
20d ago
IRD
Opus Genetics Earns Buy Rating as Advancing Gene Therapy Pipeline and De-Risked LCA5 Program Support Unchanged $10 Price Target
PremiumRatings
Opus Genetics Earns Buy Rating as Advancing Gene Therapy Pipeline and De-Risked LCA5 Program Support Unchanged $10 Price Target
23d ago
IRD
Opus Genetics price target lowered to $9 from $10 at RBC Capital
PremiumThe Fly
Opus Genetics price target lowered to $9 from $10 at RBC Capital
23d ago
IRD
Opus Genetics files $300M mixed securities shelf
PremiumThe FlyOpus Genetics files $300M mixed securities shelf
23d ago
IRD
Analyst Reiterates Buy on Opus Genetics as Pivotal OPGx‑LCA5 Trial Advances and Cash Runway Extends Into 2028
Premium
Ratings
Analyst Reiterates Buy on Opus Genetics as Pivotal OPGx‑LCA5 Trial Advances and Cash Runway Extends Into 2028
23d ago
IRD
Opus Genetics reports Q2 EPS (14c), consensus (16c)
Premium
The Fly
Opus Genetics reports Q2 EPS (14c), consensus (16c)
24d ago
IRD
IRD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
IRD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
25d ago
IRD
Opus Genetics: Advancing Gene Therapy Pipeline and Key 2026 Catalyst Support Buy Rating; $12 Price Target Reiterated
PremiumRatings
Opus Genetics: Advancing Gene Therapy Pipeline and Key 2026 Catalyst Support Buy Rating; $12 Price Target Reiterated
26d ago
IRD
Opus Genetics enrolls last patient in OPGx-LCA5 trial
PremiumThe Fly
Opus Genetics enrolls last patient in OPGx-LCA5 trial
27d ago
IRD
Opus, Cytokinetics, Albertsons, Weatherford, Paysign Shock
PremiumWeekend Updates
Opus, Cytokinetics, Albertsons, Weatherford, Paysign Shock
29d ago
ACI
IRD
CarMax, MPLX, Opus, BJ’s, CoStar Trending With Analysts
PremiumWeekend UpdatesCarMax, MPLX, Opus, BJ’s, CoStar Trending With Analysts
29d ago
BJ
IRD
Opus Genetics initiated with a Buy at TD Cowen
Premium
The Fly
Opus Genetics initiated with a Buy at TD Cowen
1M ago
IRD
Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged
Premium
Ratings
Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged
2M ago
IRD
Opus Genetics sets September timeline for retinal disease trial data
PremiumThe Fly
Opus Genetics sets September timeline for retinal disease trial data
2M ago
IRD
Yun Zhong Reiterates Buy on Opus Genetics as FDA-Backed, High-Power Phase 3 Design for OPGx-LCA5 Accelerates Path to Approval and Validates Broader Retinal Disease Pipeline
PremiumRatings
Yun Zhong Reiterates Buy on Opus Genetics as FDA-Backed, High-Power Phase 3 Design for OPGx-LCA5 Accelerates Path to Approval and Validates Broader Retinal Disease Pipeline
2M ago
IRD
Opus Genetics: FDA-Backed Phase 3 Path and Strong Early Efficacy Support Reiterated Buy on IRD with Unchanged $10 Price Target
PremiumRatings
Opus Genetics: FDA-Backed Phase 3 Path and Strong Early Efficacy Support Reiterated Buy on IRD with Unchanged $10 Price Target
2M ago
IRD
Opus Genetics FDA alignment further de-risks path to market, says Chardan
PremiumThe Fly
Opus Genetics FDA alignment further de-risks path to market, says Chardan
2M ago
IRD
Morning Movers: TeraWulf surges following lease agreement with Anthropic
PremiumThe FlyMorning Movers: TeraWulf surges following lease agreement with Anthropic
2M ago
IRD
KOS
Opus Genetics announces FDA alignment on OPGx-LCA5 trial
Premium
The Fly
Opus Genetics announces FDA alignment on OPGx-LCA5 trial
2M ago
IRD
Opus Genetics Advances New Gene Therapy Trial for Rare Childhood Blindness
Premium
Company Announcements
Opus Genetics Advances New Gene Therapy Trial for Rare Childhood Blindness
2M ago
IRD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >